Ligand Pharmaceuticals Incorporated's Customers Performance

Name: Ligand Pharmaceuticals Incorporated Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

LGND

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


LGND's Source of Revenues		During the corresponding time, Ligand Pharmaceuticals Incorporated recorded a revenue increase by 33.73 % year on year, sequentially revenue grew by 23.14 %. While revenue at the Ligand Pharmaceuticals Incorporated's corporate clients • List of LGND Customers

for the same period Ligand Pharmaceuticals Incorporated recorded revenue increase by 33.73 % year on year, sequentially revenue grew by 23.14 %.

• List of LGND Customers

Ligand Pharmaceuticals Incorporated's Business Units


Intangible Royalty Assets	110.36 %	of total Revenue
Financial Royalty Assets	32.49 %	of total Revenue
Royalty	142.86 %	of total Revenue
Material Sales, Captisol	26.11 %	of total Revenue
Contract revenue and income	12.24 %	of total Revenue
Development and Licensing of Biopharmaceutical Assets	21.91 %	of total Revenue
Filspari	39.08 %	of total Revenue
Kyprolis	11.2 %	of total Revenue
Qarziba	9.96 %	of total Revenue
Capvaxive	6.73 %	of total Revenue
Ohtuvayre inventors	4.39 %	of total Revenue
Royalty Intangible, Other	12.61 %	of total Revenue
Vaxneuvance	2.99 %	of total Revenue
Contract and Revenue Income, Other	7.85 %	of total Revenue
Contract revenue and other income	12.24 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Ligand Pharmaceuticals Incorporated's Comment on Sales, Marketing and Customers

News about Ligand Pharmaceuticals Incorporated Contracts

The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement i...

Sparsentan: A Breakthrough in IgA Nephropathy Treatment and its Impact on Ligand Pharmaceuticals The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement in the treatment of Immunoglobulin A Nephropathy (IgAN). Travere Therapeutics, in partnership with Ligand Pharmaceuticals, has developed sparsentan, the first non-immunosuppressive therapy that effectively slows kidney function decline in adults with primary IgAN. This approval not only presents a promising treatment option for patients but also signifies a noteworthy milestone for Ligand Pharmaceuticals. In this article, we explore the key facts surrounding this development and assess its potential impact on Ligand Pharmaceut...

FDA Approves Ohtuvayre (Ensifentrine) First Inhaled Therapy with Novel Mechanism for COPD in Over 20 Years ...

: The approval of Ohtuvayre (ensifentrine) by the U.S. Food and Drug Administration (FDA) marks pivotal progress in the treatment paradigm of chronic obstructive pulmonary disease (COPD). Developed by Verona Pharma plc in collaboration with Ligand Pharmaceuticals Incorporated, Ohtuvayre stands as the first inhaled drug with a novel mechanism of action for the maintenance treatment of COPD in over 20 years. This article discusses the significance of this approval, the innovative mechanism of Ohtuvayre, its clinical efficacy, safety profile, and its potential impact on patient outcomes and future COPD treatment strategies. Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mo...

LGND's Stock Performance relative to it's Customers

LGND's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Ligand Pharmaceuticals Incorporated	5,974.17	274.48	153.56	47
SUBTOTAL	0.00	0.00	0.00	-

Sources: Ligand Pharmaceuticals Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ligand Pharmaceuticals Incorporated’s corporate clients.
For your research, we’ve provided 9 tables on Ligand Pharmaceuticals Incorporated corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.